Japan Duchenne Muscular Dystrophy Market Research Report 2018

Publisher Name :
Date: 06-Apr-2018
No. of pages: 124
Inquire Before Buying

This report studies the Duchenne Muscular Dystrophy market status and outlook of Japan and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in Japan and major regions, and splits the Duchenne Muscular Dystrophy market by product type and applications/end industries.

The major players in Japan Duchenne Muscular Dystrophy market include

PTC Therapeutics

Sarepta Therapeutics

Bristol-Myers Squibb

ITALFARMACO

BioMarin

Daiichi Sankyo

Solid Biosciences

Summit Therapeutics

FibroGen

NS Pharma

Pfizer

ReveraGen BioPharma

Wave Life

Genethon

Santhera Pharmaceuticals

Geographically, this report is segmented into several key Regions, with consumption, revenue, market share and growth rate of Duchenne Muscular Dystrophy in these regions, from 2013 to 2025 (forecast), covering

Kanto

Hokkaido & Tohoku

Chubu

Kyushu

Others

On the basis of product, the Duchenne Muscular Dystrophy market is primarily split into

Deflazacort

Prednisone

Others

On the basis on the end users/applications, this report covers

Male

Female

Japan Duchenne Muscular Dystrophy Market Research Report 2018

Table of Contents
1 Duchenne Muscular Dystrophy Overview 1
1.1 Product Overview and Scope of Duchenne Muscular Dystrophy 1
1.2 Classification of Duchenne Muscular Dystrophy by Product Category 2
1.2.1 Japan Duchenne Muscular Dystrophy Revenue Comparison by Types (2013-2025) 2
1.2.2 Japan Duchenne Muscular Dystrophy Revenue Market Share by Types in 2017 3
1.2.3 Prednisone 4
1.2.4 Deflazacort 5
1.3 Japan Duchenne Muscular Dystrophy Market by Applications/End Users 5
1.3.1 Male 6
1.3.2 Female 7
1.4 Japan Duchenne Muscular Dystrophy Market by Regions 7
1.4.1 Japan Duchenne Muscular Dystrophy Market Size Comparison by Regions (2013-2025) 7
1.4.2 Kanto Duchenne Muscular Dystrophy Status and Prospect (2013-2025) 8
1.4.3 Hokkaido & Tohoku Duchenne Muscular Dystrophy Status and Prospect (2013-2025) 9
1.4.4 Chubu Duchenne Muscular Dystrophy Status and Prospect (2013-2025) 10
1.4.5 Kyushu Duchenne Muscular Dystrophy Status and Prospect (2013-2025) 11
1.5 Japan Market Size of Duchenne Muscular Dystrophy (2013-2025) 12
2 Global Duchenne Muscular Dystrophy Market Competition by Players/Manufacturers 13
2.1 Global Duchenne Muscular Dystrophy Sales and Market Share of Key Players/Manufacturers (2017-2018) 13
2.2 Global Duchenne Muscular Dystrophy Revenue and Share by Players/Manufacturers (2017-2018) 14
2.3 Global Duchenne Muscular Dystrophy Average Price by Players/Manufacturers (2017-2018) 14
2.4 Global Market Size of Duchenne Muscular Dystrophy (2013-2018) 15
2.5 Global Players/Manufacturers Duchenne Muscular Dystrophy Headquarters, Established Date and Product Types 15
3 Japan Duchenne Muscular Dystrophy Revenue by Regions (2013-2018) 20
4 Japan Duchenne Muscular Dystrophy Revenue by Type/ Product Category (2013-2018) 23
4.1 Japan Duchenne Muscular Dystrophy Revenue and Market Share by Type (2013-2018) 23
4.2 Japan Duchenne Muscular Dystrophy Revenue Growth Rate by Type (2013-2018) 26
5 Japan Duchenne Muscular Dystrophy Revenue by Application (2013-2018) 27
5.1 Japan Duchenne Muscular Dystrophy Revenue and Market Share by Applications (2013-2018) 27
5.2 Japan Duchenne Muscular Dystrophy Revenue Growth Rate by Applications (2013-2018) 30
6 Analysis of Duchenne Muscular Dystrophy Industry Key Manufacturers 31
6.1 PTC Therapeutics 31
6.1.1 Company Profile 31
6.1.2 Product Information 32
6.1.3 Sales, Price, Cost, Gross, and Revenue 32
6.2 Sarepta Therapeutics 33
6.2.1 Company Profile 33
6.2.2 Product Information 34
6.2.3 Sales, Price, Cost, Gross, and Revenue 34
6.3 Bristol-Myers Squibb 35
6.3.1 Company Profile 35
6.3.2 Product Information 36
6.3.3 Product Name and Clinical Stage 36
6.4 ITALFARMACO 37
6.4.1 Company Profile 37
6.4.2 Product Information 38
6.4.3 Product Name and Clinical Stage 38
6.5 BioMarin 39
6.5.1 Company Profile 39
6.5.2 Product Information 39
6.5.3 Product Name and Clinical Stage 40
6.6 Daiichi Sankyo 40
6.6.1 Company Profile 40
6.6.2 Product Information 41
6.6.3 Product Name and Clinical Stage 41
6.7 Solid Biosciences 42
6.7.1 Company Profile 42
6.7.2 Product Information 43
6.7.3 Product Name and Clinical Stage 43
6.8 Summit Therapeutics 43
6.8.1 Company Profile 43
6.8.2 Product Information 44
6.8.3 Product Name and Clinical Stage 45
6.9 FibroGen 45
6.9.1 Company Profile 45
6.9.2 Product Information 46
6.9.3 Product Name and Clinical Stage 47
6.10 NS Pharma 47
6.10.1 Company Profile 47
6.10.2 Product Information 48
6.10.3 Product Name and Clinical Stage 48
6.11 Pfizer 49
6.11.1 Company Profile 49
6.11.2 Product Information 50
6.11.3 Product Name and Clinical Stage 50
6.12 ReveraGen BioPharma 50
6.12.1 Company Profile 50
6.12.2 Product Information 51
6.12.3 Product Name and Clinical Stage 52
6.13 Wave Life 52
6.13.1 Company Profile 52
6.13.2 Product Information 53
6.13.3 Product Name and Clinical Stage 54
6.14 Genethon 54
6.14.1 Company Profile 54
6.14.2 Product Information 55
6.14.3 Product Name and Clinical Stage 55
6.15 Santhera Pharmaceuticals 56
6.15.1 Company Profile 56
6.15.2 Product Information 57
6.15.3 Product Name and Clinical Stage 57
7 Duchenne Muscular Dystrophy Manufacturing Cost Analysis 58
7.1 Duchenne Muscular Dystrophy R&D Cost Analysis 58
7.1.1 Clinical Phase Costs 59
7.1.2 Capitalized Costs 60
7.2 Proportion of Manufacturing Cost Structure 61
7.2.1 Raw Materials 61
7.2.2 Labor Cost 62
7.2.2.1 USA Labor Cost Analysis 63
7.2.2.2 Europe Labor Costs Analysis 65
7.2.2.3 Asia Labor Costs Analysis 67
7.2.3 Manufacturing Expenses 69
7.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy 70
8 Industrial Chain, Sourcing Strategy and Downstream Buyers 71
8.1 Duchenne Muscular Dystrophy Industrial Chain Analysis 71
8.2 Upstream Raw Materials Sourcing 72
8.3 Downstream Buyers 72
9 Marketing Strategy Analysis, Distributors/Traders 74
9.1 Marketing Channel 74
9.1.1 Direct Marketing 74
9.1.2 Indirect Marketing 75
9.1.3 Marketing Channel Development Trend 76
9.2 Market Positioning 76
9.2.1 Pricing Strategy 76
9.2.2 Brand Strategy 79
9.2.3 Target Client 80
10 Market Effect Factors Analysis 81
10.1 Technology Progress/Risk 81
10.1.1 Substitutes Threat 81
10.1.2 Technology Progress in Related Industry 82
10.2 Consumer Needs/Customer Preference Change 85
10.3 Economic/Political Environmental Change 85
11 Japan Duchenne Muscular Dystrophy Market Size Forecast (2019-2025) 95
11.1 Japan Duchenne Muscular Dystrophy Revenue Forecast (2019-2025) 95
11.2 Japan Duchenne Muscular Dystrophy Revenue Forecast by Type (2019-2025) 96
11.3 Japan Duchenne Muscular Dystrophy Revenue Forecast by Application (2019-2025) 98
11.4 Japan Duchenne Muscular Dystrophy Revenue Forecast by Regions (2019-2025) 101
12 Research Findings and Conclusion 105
13 Methodology and Data Source 106
13.1 Methodology/Research Approach 106
13.1.1 Research Programs/Design 106
13.1.2 Market Size Estimation 107
13.1.3 Market Breakdown and Data Triangulation 109
13.2 Data Source 110
13.2.1 Secondary Sources 110
13.2.2 Primary Sources 110
13.3 Disclaimer 111
13.4 Author List 112
List of Tables and Figures
Figure Product Picture of Duchenne Muscular Dystrophy 1
Figure Japan Duchenne Muscular Dystrophy Revenue (M USD) and Growth Rate Comparison by Types (Product Category) (2013-2025) 2
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share by Types in 2017 3
Figure Pain Management Drugs Product Picture 4
Figure Corticosteroids Product Picture 5
Table Japan Duchenne Muscular Dystrophy Revenue (M USD) Comparison by Applications (2013-2025) 5
Figure Japan Revenue Market Share of Duchenne Muscular Dystrophy by Applications in 2017 6
Figure Male Examples 6
Figure Female Examples 7
Table Japan Duchenne Muscular Dystrophy Market Size Comparison by Regions (2013-2025) 7
Figure Kanto Duchenne Muscular Dystrophy Revenue (M USD) and Growth Rate (2013-2025) 8
Figure Hokkaido & Tohoku Duchenne Muscular Dystrophy Revenue (M USD) and Growth Rate (2013-2025) 9
Figure Chubu Duchenne Muscular Dystrophy Revenue (M USD) and Growth Rate (2013-2025) 10
Figure Kyushu Duchenne Muscular Dystrophy Revenue (M USD) and Growth Rate (2013-2025) 11
Figure Japan Duchenne Muscular Dystrophy Revenue (M USD) and Growth Rate (2013-2025) 12
Table Global Duchenne Muscular Dystrophy Sales (K Dose) of Key Players/Manufacturers (2017-2018) 13
Table Global Duchenne Muscular Dystrophy Sales Market Share by Players/Manufacturers (2017-2018) 13
Table Global Duchenne Muscular Dystrophy Revenue (M USD) by Players/Manufacturers (2017-2018) 14
Table Global Duchenne Muscular Dystrophy Revenue Market Share by Players/Manufacturers (2017-2018) 14
Table Global Market Duchenne Muscular Dystrophy Average Price (USD/Dose) of Key Players/Manufacturers (2017-2018) 14
Figure Global Duchenne Muscular Dystrophy Revenue (M USD) and Growth Rate (2013-2025) 15
Table Japan Players/Manufacturers Duchenne Muscular Dystrophy Headquarters and Established Date 15
Table Japan Players/Manufacturers Duchenne Muscular Dystrophy Product Category and Stage 16
Table Mergers & Acquisitions, Expansion 16
Table Japan Duchenne Muscular Dystrophy Revenue (M USD) and Market Share by Regions (2013-2018) 20
Table Japan Duchenne Muscular Dystrophy Revenue Market Share by Regions (2013-2018) 20
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share by Regions (2013-2018) 21
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share by Regions in 2013 21
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share by Regions in 2017 22
Table Japan Duchenne Muscular Dystrophy Revenue (M USD) and Market Share by Type (2013-2018) 23
Table Japan Duchenne Muscular Dystrophy Revenue Market Share by Type (2013-2018) 23
Figure Revenue Market Share of Duchenne Muscular Dystrophy by Type (2013-2018) 24
Figure Revenue Market Share of Duchenne Muscular Dystrophy by Type in 2013 24
Figure Revenue Market Share of Duchenne Muscular Dystrophy by Type in 2017 25
Figure Japan Duchenne Muscular Dystrophy Revenue Growth Rate by Type (2013-2018) 26
Table Japan Duchenne Muscular Dystrophy Revenue (M USD) by Applications (2013-2018) 27
Table Japan Duchenne Muscular Dystrophy Revenue Market Share by Applications (2013-2018) 27
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share by Applications (2013-2018) 28
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share by Applications in 2013 28
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share by Applications in 2017 29
Figure Japan Duchenne Muscular Dystrophy Revenue Growth Rate by Applications (2013-2018) 30
Table PTC Therapeutics Company Profile 31
Figure Duchenne Muscular Dystrophy Product Picture of PTC Therapeutics 32
Table Duchenne Muscular Dystrophy Sales (K Dose), Price (USD/Dose), Cost (USD/Dose), Gross (USD/Dose), Revenue (M USD) and Gross Margin of PTC Therapeutics 2017-2018 32
Table Sarepta Therapeutics Company Profile 33
Figure Duchenne Muscular Dystrophy Product Picture of Sarepta Therapeutics 34
Table Duchenne Muscular Dystrophy Sales (K Dose), Price (USD/Dose), Cost (USD/Dose), Gross (USD/Dose), Revenue (M USD) and Gross Margin of Sarepta Therapeutics 2017-2018 34
Table Bristol-Myers Squibb Company Profile 35
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of Bristol-Myers Squibb 36
Table ITALFARMACO Company Profile 37
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of ITALFARMACO 38
Table BioMarin Company Profile 39
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of BioMarin 40
Table Daiichi Sankyo Company Profile 40
Figure Duchenne Muscular Dystrophy Product Picture of Daiichi Sankyo 41
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of Daiichi Sankyo 41
Table Solid Biosciences Company Profile 42
Figure Duchenne Muscular Dystrophy Product Picture of Solid Biosciences 43
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of Solid Biosciences 43
Table Summit Therapeutics Company Profile 43
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of Summit Therapeutics 45
Table FibroGen Company Profile 45
Figure Duchenne Muscular Dystrophy Product Picture of FibroGen 46
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of FibroGen 47
Table NS Pharma Company Profile 47
Figure Duchenne Muscular Dystrophy Product Picture of NS Pharma 48
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of NS Pharma 48
Table Pfizer Company Profile 49
Figure Duchenne Muscular Dystrophy Product Picture of Pfizer 50
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of Pfizer 50
Table ReveraGen BioPharma Company Profile 50
Figure Duchenne Muscular Dystrophy Product Picture of ReveraGen BioPharma 52
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of ReveraGen BioPharma 52
Table Wave Life Company Profile 52
Figure Duchenne Muscular Dystrophy Product Picture of Wave Life 53
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of Wave Life 54
Table Genethon Company Profile 54
Figure Duchenne Muscular Dystrophy Product Picture of Genethon 55
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of Genethon 55
Table Santhera Pharmaceuticals Company Profile 56
Table Duchenne Muscular Dystrophy Product Name and Clinical Stage of Santhera Pharmaceuticals 57
Figure Typical Phases from Research to the Market for a drug Candidate 59
Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound 60
Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound 61
Table Manufacturing Cost Structure of Duchenne Muscular Dystrophy 61
Figure Assessment of API Manufacturing Cost By Region 62
Figure USA Overview of Average Hourly Wages 2015-2016 (USD/Hour) 63
Figure USA Overview of Labor Costs 2013-2016 (110 Index Points) 63
Figure Cost of Employing a Factory Worker 65
Figure 2015 Estimated Labor Costs for the Whole Economy in Europe 66
Figure Monthly Minimum Wages in Asia 2016 67
Figure China Overview of Average Yearly Wages 2015-2016 (CNY/Year) 68
Figure Japan Overview of Average Monthly Wages 2015-2016(JPY Thousand/Month) 68
Table 2015 Global Electricity Price of Industry (USD/KWh) by Country 69
Figure Manufacturing Process Analysis of Duchenne Muscular Dystrophy 70
Figure Duchenne Muscular Dystrophy Industrial Chain Analysis 71
Table Major Buyers of Duchenne Muscular Dystrophy 72
Figure Setting Pricing Policy 77
Figure PMO Structure 83
Figure RNA Structure 84
Figure Next-generation Chemistries 85
Figure Global GDP Growth Rate for 2016 86
Figure Real GDP Growth 2016-2020 annual Average 87
Figure US GDP 2006-2016 (Billion USD) 88
Figure US CPI Change 2017-2018 88
Figure EU GDP 2008-2016 (Billion USD) 89
Figure EU CPI Change 2017 89
Figure Germany GDP 2008-2016 (Billion USD) 90
Figure Germany CPI Change 2017-2018 90
Figure UK GDP 2008-2016 (Billion USD) 91
Figure UK CPI Change 2016-2017 91
Figure Italy GDP 2008-2016 (Billion USD) 92
Figure Italy CPI Change 2017-2018 92
Figure Japan GDP 2008-2016 (Billion USD) 93
Figure Japan CPI Change 2017 93
Figure China GDP 2008-2016 (Billion USD) 94
Figure China CPI Change 2017-2018 94
Figure Japan Duchenne Muscular Dystrophy Revenue (M USD) and Growth Rate Forecast (2019-2025) 95
Table Japan Duchenne Muscular Dystrophy Revenue (M USD) Forecast by Type (2019-2025) 96
Table Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Type (2019-2025) 96
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Type (2019-2025) 97
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Type in 2019 97
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Type in 2025 98
Table Japan Duchenne Muscular Dystrophy Revenue (M USD) Forecast by Application (2019-2025) 98
Table Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Application (2019-2025) 98
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Application (2019-2025) 99
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Application in 2019 100
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Application in 2025 101
Table Japan Duchenne Muscular Dystrophy Revenue (M USD) Forecast by Regions (2019-2025) 101
Table Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Regions (2019-2025) 102
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Regions (2019-2025) 102
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Regions in 2019 103
Figure Japan Duchenne Muscular Dystrophy Revenue Market Share Forecast by Regions in 2025 104
Table Research Programs/Design for This Report 106
Figure Bottom-up and Top-down Approaches for This Report 108
Figure Data Triangulation 109
Table Key Data Information from Secondary Sources 110
Table Key Data Information from Primary Sources 111
  • Global Myelodysplastic Syndrome Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 128
    Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.[2] Early on there are typically no symptoms.Later symptoms may include feeling tired, shortness of breath, easy bleeding, or frequent infections.[2] Some types may develop into acute myeloid leukemia. The presence of diagnostic tools is the key driver for the growth of this market. Diagnosis techniques like blood count, peri......
  • Global Myasthenia Gravis Drugs Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 120
    Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance. The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market's growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal ......
  • Global MRSA Drugs Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 122
    Staphylococcus aureus is a bacteria commonly found on nose or skin of healthy people. MRSA i.e., methicillin-resistant staphylococcus aureus, is thus a type of staphylococcus aureus that is resistant to beta-lactam antibiotic called methicillin. MRSA strains do not respond to methicillin treatment. Around 1% of the population carrying staphylococcus aureus on their nose or skin are infected by MRSA. The infection causes skin and tissue infection, and is transmitted by direct skin-to-skin contact......
  • Global Fibrin Sealants Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 125
    Fibrin sealant, a two-component substance consisting of thrombin and fibrinogen, is used as a hemostatic or adhesive in various surgical solutions. In clinical practice, a fibrin sealant consists of a concentrated solution of fibrinogen and Factor XIII, which combine with a solution of calcium and thrombin to form a coagulum that stimulates clotting. Beriplast P and TISSEEL are some of the commercially available fibrin sealants. The Americas accounted for 48% of the market share during th......
  • Global Female Contraceptive Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 110
    Female contraceptives, also known as female birth control are methods of preventing pregnancy that primarily involve the female physiology. Female contraceptive devices account for major shares of the contraceptive pills market throughout the forecast period. The increasing adoption of female contraceptive devices will drive the growth of this product segment in the female contraceptive market. The Americas will be the major revenue contributor to the contraceptive pills market thr......
  • Global Female Condoms Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 114
    A female condom is a birth control device that acts as a barrier to prevent sexual fluids from entering the vagina during intercourse. It protects against pregnancy and sexually transmitted infections (STIs). The online stores will be the fastest-growing segment and will continue to maintain its lead in the global market. Much of the segment's growth is due to its higher penetration rate and adoptability. Female condoms are easily accessible online and allow for useful comparison in terms......
  • Global Excipients Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 111
    Excipients are inert substances that are generally used to manufacture different forms of drugs and are present in the finished products. Excipients help in providing long-term stability and make solid formulations bulkier. They also improve the functionality of drugs and make them safer. Based on functionality, the pharmaceutical excipients market is segmented into fillers & diluents, binders, suspending & viscosity agents, flavoring agents & sweeteners, coating agents, colorants, disint......
  • Global Consumer Healthcare Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 127
    Consumer healthcare products include trusted brands of multivitamins and iron supplements, in addition to products for allergies, personal hygiene, sleep support, alertness and cold and flu. Consumer health products do not require a written prescription from healthcare professionals but can be purchased directly from a pharmacy store. The global Consumer Healthcare market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx%......
  • Global Intravenous (IV) Ibuprofen Market Insights, Forecast to 2025
    Published: 18-Jan-2019        Price: US 3900 Onwards        Pages: 114
    Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation occurred due to a disease, operative procedures or trauma, and acute illness. The global Intravenous (IV) Ibuprofen market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Intravenous (IV) Ibuprofen ma......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs